Western blot analysis of extracts from HCT 116, PC-12, and COS-7 cell lines using LSD2 (E1R6O) Rabbit mAb.
Western blot analysis of extracts from wild-type (WT), LSD2 knockout (LSD2 KO), and LSD1 knockout (LSD1 KO) HeLa cells using LSD2 (E1R6O) Rabbit mAb (upper) and α-Actinin (D6F6) XP® Rabbit mAb #6487 (lower). As expected, LSD2 is still expressed in LSD1 knockout HeLa cells.
|REACTIVITY||H M R Mk|
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody product webpage for recommended antibody dilution.
From sample preparation to detection, the reagents you need for your Western Blot are now in one convenient kit: #12957 Western Blotting Application Solutions Kit
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
posted June 2005
revised June 2020
Protocol Id: 10
LSD2 (E1R6O) Rabbit mAb recognizes endogenous levels of total LSD2 protein. This antibody does not cross-react with LSD1 protein.
Human, Mouse, Rat, Monkey
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu467 of human LSD2 protein.
Lysine-specific demethylase 2 (LSD2; also known as AOF1) is a nuclear amine oxidase homolog that acts as a histone demethylase and transcription cofactor protein (1,2). LSD2 functions as a co-repressor protein by demethylating mono-methyl and di-methyl histone H3 Lys4, two marks associated with actively transcribed genes (1,2). LSD2-mediated demethylation of histone H3 Lys4 is required for establishing proper DNA methylation imprints during oogenesis (3). In addition, LSD2 appears to be overexpressed in malignant breast cancers, where it contributes to DNA methylation and repression of multiple tumor suppressor genes (4,5). Furthermore, LSD2 also contains E3 ubiquitin ligase activity that targets O-GlcNac transferase (OGT) for proteosomal degradation (6). A549 lung cancer cell growth is dependent on this E3 ubiquitin ligase activity, suggesting that this function of LSD2 is also important for proper gene regulation (6).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.